Novartis takes home rights to Lubris’ eye drug
Novartis has elected to exercise an option to in-license experimental eye drug ECF843 from US biopharma Lubris.
Read More
Tag: dry eye
US approves Shire’s eye disease drug
Shire’s Xiidra has been approved by US regulators to treat the signs and symptoms of dry eye disease, giving patients access to the first prescription eye drop specifically approved for the condition.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
